市場調査レポート

米国の整形外科用生物学的・組織培養製品市場

U.S. Markets for Orthopedic Biologic and Tissue Engineered Products

発行 Medtech Insight 商品コード 329801
出版日 ページ情報 英文 116 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
米国の整形外科用生物学的・組織培養製品市場 U.S. Markets for Orthopedic Biologic and Tissue Engineered Products
出版日: 2015年05月01日 ページ情報: 英文 116 Pages
概要

当レポートでは、米国の整形外科用生物学的・組織培養製品市場について調査分析し、新興・既存の細胞療法、主要な成長影響要因、市場シェアと売上高、新しい細胞療法を開発中のバイオ技術企業、主要サプライヤーの製品ポートフォリオなど、体系的な情報を提供しています。

第1章 筋骨格系疾患/障害の概要

  • 背痛と脊椎脊髄外科
  • 手根管症候群
  • デュシェンヌ型筋ジストロフィー
  • 変形性関節症
  • 骨粗鬆症と骨折
  • 関節リウマチ

第2章 米国の生物学的筋骨格系軟組織再生・修復製品市場

  • 軟骨再生・修復技術
  • 靱帯・腱修復技術
  • 半月板修復・再生技術

第3章 米国の生物学的筋骨格系硬組織再生・修復市場

  • 市販/開発中の骨移植片・代用骨
  • 増殖因子ベースの骨移植片
  • その他の現在利用できる/開発中の生物製剤
  • 軟・硬組織修復・再生の細胞療法の新領域
  • 米国の筋骨格系硬組織再生・修復製品市場
  • 市場サマリー:硬・軟組織培養・細胞療法製品

付録:企業リスト

目次
Product Code: A428

Biologics and cellular therapies for musculoskeletal injuries-including hard tissue (i.e., bone) and soft tissue (i.e., cartilage, ligaments, and tendons)-represent a billion dollar market that is showing the potential for continued growth. Over the forecast period covered in this report, the estimated value of the U.S. market for orthopedic biologic and tissue engineered products is expected to grow by approximately $984.4 million at a compound annual growth rate (CAGR) of 8.2% to $3,014.1 million; of this holistic market, biologic and cellular therapies for hard musculoskeletal tissue are forecasted to grow at a CAGR of 7.2%, while soft musculoskeletal tissue products will grow at a CAGR of 10.6%.

This report will cover:

  • emerging and existing cellular therapies for hard and soft musculoskeletal tissue repair and regeneration;
  • key factors influencing the growth of individual product markets;
  • estimated market shares and sales among major U.S. suppliers
  • companies and biotech firms developing novel cellular therapies; and,
  • major supplier product portfolio analysis in individual product markets.

The scope of the analysis of this report covers companies developing and distributing biologics and novel cellular therapeutics for the treatment of musculoskeletal injuries. Hard tissue musculoskeletal products covered in this report include bone allograft and machined bone, demineralized bone matrix, growth factor-based bone grafts, cellular bone matrices, and select other biologics. Soft tissue musculoskeletal products covered by this report include cartilage regeneration and repair products, ligament and tendon repair technologies, and meniscus repair and regeneration products.

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

Table of Contents

EXECUTIVE SUMMARY

  • i. Methodology
  • Exhibit ES-1: 2014, U.S. Orthopedic Biologic and Tissue Engineered Products Market, Share by Products

1. OVERVIEW OF MUSCULOSKELETAL DISEASES/DISORDERS

  • 1.1 Back Pain and Spine Surgery
  • 1.2 Carpal Tunnel Syndrome
  • 1.3 Duchenne Muscular Dystrophy
  • 1.4 Osteoarthritis
  • 1.5 Osteoporosis and Fractures
  • 1.6 Rheumatoid Arthritis
  • Exhibit 1-1: Musculoskeletal Surgery, Procedure Volumes Forecast, by Type, 2014-2019

2. U.S. MARKETS FOR BIOLOGIC MUSCULOSKELETAL SOFT TISSUE REGENERATION AND REPAIR PRODUCTS

  • 2.1 Cartilage Regeneration and Repair Technologies
    • 2.1.1 Currently Available Products
      • 2.1.1.1 Arthrex
      • 2.1.1.2 Vericel
      • 2.1.1.3 Zimmer
    • 2.1.2 Products in Development
      • 2.1.2.1 CellCoTec
      • 2.1.2.2 Cytori Therapeutics
      • 2.1.2.3 Histogenics
      • 2.1.2.4 ISTO Technologies
      • 2.1.2.5 Medipost
      • 2.1.2.6 TETEC
      • 2.1.2.7 TiGenix
      • 2.1.2.8 TissueGene
    • 2.1.3 Market Forecast
    • 2.1.4 Competitive Analysis
  • 2.2 Ligament and Tendon Repair Technologies
    • 2.2.1 Graft-Based Products Overview
    • 2.2.2 Tissue Engineering
      • 2.2.2.1 Biologic Scaffolds
      • 2.2.2.2 Developmental Biologic Scaffolds
    • 2.2.3 Market Forecast
    • 2.2.4 Competitive Analysis
  • 2.3 Meniscus Repair and Regeneration Technologies
    • 2.3.1 Products Overview
    • 2.3.2 Market Forecast
    • 2.3.3 Competitive Analysis
    • 2.2.4 U.S. Markets for Biologic Soft Tissue Regeneration and Repair Products
  • Exhibit 2-1: 2014, Cartilage Repair Procedures
  • Exhibit 2-2: Cartilage Repair and Regeneration Products, Market Forecast, 2014-2019
  • Exhibit 2-3: 2014, Knee Cartilage Repair and Regeneration Products Market, Share by Supplier
  • Exhibit 2-4: 2015, Selected Allografts for Ligament and Tendon Replacement
  • Exhibit 2-5: 2015, Biologic Scaffolds and Matrices for Ligament and Tendon Repair
  • Exhibit 2-6: Ligament and Tendon Replacement and Regeneration Products, Market Forecast, 2014-2019
  • Exhibit 2-7: 2014, Ligament and Tendon Replacement and Regeneration Products Market, Share by Supplier
  • Exhibit 2-8: 2015, Selected Biologic Meniscal Repair Products
  • Exhibit 2-9: Meniscal Replacement and Regeneration Products, Market Forecast, 2014-2019
  • Exhibit 2-10: 2014, Meniscal Replacement and Regeneration Products Market, Share by Supplier
  • Exhibit 2-11: Musculoskeletal Soft Tissue Biologics Products, Market Forecast, 2014-2019

3. U.S. MARKETS FOR BIOLOGIC MUSCULOSKELETAL HARD TISSUE REGENERATION AND REPAIR

  • 3.1 Bone Graft and Bone Substitute Products on the Market and Under Development
    • 3.1.1 Bone Autograft
    • 3.1.2 Bone Allografts and Machined Bone
    • 3.1.3 Demineralized Bone Matrix
    • 3.1.4 Market Forecast
    • 3.1.5 Competitive Analysis
  • 3.2 Growth Factor-Based Bone Grafts
    • 3.2.1 Products Overview
      • 3.2.1.1 Bioventus
      • 3.2.1.2 Medtronic
      • 3.2.1.3 Wright Medical Technology
    • 3.2.2 Market Forecast
    • 3.2.3 Competitive Analysis
  • 3.3 Other Biologics Currently Available or in Development
    • 3.3.1 Cellular Bone Matrices
      • 3.3.1.1 AlloSource
      • 3.3.1.2 Biomet
      • 3.3.1.3 NuVasive
      • 3.3.1.4 Orthofix
      • 3.3.1.5 Osiris Therapeutics
      • 3.3.1.6 RTI Surgical
    • 3.3.2 Cellular Regeneration Therapies in Development for Hard Bone Musculoskeletal Repair
      • 3.3.2.1 Cerapedics, Inc.
      • 3.3.2.2 Ferring Pharmaceuticals
      • 3.3.2.3 Mesoblast
    • 3.3.3 Market Forecast
    • 3.3.4 Competitive Analysis
  • 3.4 Emerging Areas of Cellular Therapy for Soft and Hard Tissue Repair and Regeneration
    • 3.4.1 Bone Marrow Aspirate Concentrate
    • 3.4.2 Gene Therapy
      • 3.4.2.1 Systemic Gene Therapy
      • 3.4.2.2 Regional Gene Therapy
    • 3.4.3 Three-Dimensional Printing
  • 3.5 U.S. Markets for Musculoskeletal Hard Tissue Regeneration and Repair Products
  • 3.6 Combined Market Summary for Hard and Soft Tissue Engineering and Cellular Therapy Products
  • Exhibit 3-1: 2015, Description and Representative Pricing of Base Allografts Used in Spine Surgery
  • Exhibit 3-2: 2015, Selected Bone Allograft and Machined Bone Products
  • Exhibit 3-3: 2015, Selected Demineralized Bone Matrix Products
  • Exhibit 3-4: Bone Allografts and Synthetic Bone Graft Substitutes, Market Forecast, 2014-2019
  • Exhibit 3-5: 2014, Bone Allograft Products Market, Share by Supplier
  • Exhibit 3-6: 2014, Demineralized Bone Matrix Products Market, Share by Supplier
  • Exhibit 3-7: Growth Factor-Based Products, Market Forecast, 2014-2019
  • Exhibit 3-8: 2014, Growth Factor-Based Products Market, Share by Supplier
  • Exhibit 3-9: Stem Cell Matrices and Other Osteobiologic Agents for Bone Healing and Enhancement of Spinal Fusion, Market Forecast, 2014-2019
  • Exhibit 3-10: 2014, Market Shares of Stem Cell Applications for Bone Healing and Spinal Fusion by Application
  • Exhibit 3-11: 2014, Stem Cell Products and Other Orthobiologics for Bone Healing and Spinal Fusion, Share by Supplier
  • Exhibit 3-12: U.S. Biologic Products for Musculoskeletal Hard Tissue Repair and Regeneration, Combined Market Forecast, 2014-2019
  • Exhibit 3-13: U.S. Hard and Soft Musculoskeletal Tissue Repair and Regeneration, Combined Procedure Volumes, 2014-2019
  • Exhibit 3-14: U.S. Biologic Products for Musculoskeletal Hard and Soft Tissue Repair and Regeneration, Combined Market Forecast, 2014-2019

APPENDIX: COMPANY LISTING

BIBLIOGRAPHY

Back to Top